Washington

Global health R&D delivers for Washington

Click here to select a new state

Select a new state

US government investment in global health R&D has delivered

$3 billion

to Washington research institutions

37,500+ new jobs

for Washington

Washington's top USG-funded global health R&D institutions

Fred Hutchinson Cancer Research Center (including the HIV Vaccine Trials Network)

$1.8 billion

University of Washington (including Harborview Medical Center)

$468 million

Seattle Children's Hospital (including Seattle Children's Research Institute and Center for Global Infectious Disease Research)

$359.6 million

Access to Advanced Health Institute (AAHI) (formerly Infectious Disease Research Institute)

$85.5 million

PATH (including Meningitis Vaccine Project and Malaria Vaccine Initiative)

$64.3 million

Benaroya Research Institute at Virginia Mason

$45.8 million

The Geneva Foundation

$28.5 million

HDT Bio

$20 million

PAI Life Sciences (formerly Protein Advances Inc.)

$19 million

Institute for Systems Biology

$18.7 million

InBios International Inc.

$16 million

Washington State University

$12.8 million

Kineta

$10 million

Pacific Northwest National Laboratory

$5.4 million

Etubics

$4.6 million

Group Health Cooperative*

$4.6 million

Orlance Inc.

$2.7 million

Scisco Genetics Inc.

$2.6 million

Lumen Bioscience

$2.2 million

SpringStar Inc.*

$1.2 million

Tasso Inc.

$1.2 million

TRIA Bioscience Corp.*

$793 thousand

Allen Institute

$778 thousand

Phage Diagnostics

$736 thousand

Syntrix Biosystems

$710 thousand

Gonzaga University

$622 thousand

MalarVX

$612 thousand

Glyciome

$487 thousand

Lamprogen Inc.

$464 thousand

Central Washington University

$446 thousand

ID Genomics

$323 thousand

Nortis Bio

$289 thousand

Cyrus Biotechnology (including Orthogonal Biologics)

$277 thousand

AttoDx

$272 thousand

Maren-Go Solutions Corporation

$54 thousand

Emerald Biostructures*

$26 thousand

Washington's top areas of global health R&D by USG funding

14%

COVID-19

57%

HIV/AIDS

6.6%

Malaria

3.8%

Neglected tropical diseases

Buruli ulcer

Dengue

Helminth infections (Worms & Flukes)

Kinetoplastid diseases

Leprosy

9.7%

Tuberculosis

8.8%

Other

Arenaviral hemorrhagic fevers (including Lassa fever)

Bacterial pneumonia & meningitis

Bunyaviral diseases (including CCHF, RVF, SFTS)

Chikungunya

Diarrheal diseases

Emergent non-polio enteroviruses (including EV71, D68)

Filoviral diseases (including Ebola, Marburg)

Henipaviral diseases (including Nipah)

Hepatitis B

Hepatitis C

Mpox

Multi-disease/health area R&D

Other coronaviruses (including MERS, SARS)

Reproductive health

Salmonella infections

Zika

Neglected and emerging diseases in Washington

Chikungunya cases

Dengue cases

HIV diagnoses

7297

Malaria cases

240

Mpox cases

291

Tuberculosis cases

1627

Global health R&D at work in Washington

Several million babies born each year in Africa and Asia cannot breastfeed due to prematurity or cleft lip or palate. Tools such as breast pumps and bottles are impractical and unhygienic in settings that lack clean water and electricity. To help save these infants from starving, the University of Washington, Seattle Children’s Hospital, and PATH developed the NIFTY cup, a soft, silicone bowl with a tiny reservoir that allows these infants to lap up lifesaving breast milk. Since 1996, more than 80,000 cups have been distributed in more than 40 countries worldwide.

Footnotes

Methodology
US government global health R&D investment (total to state, top funded institutions, top health areas): Authors’ analysis of USG investment data from the G-FINDER survey following identification of state location of funding recipients. Reflects funding for basic research and product development for neglected diseases from 2007 to 2022, for emerging infectious diseases from 2014–2022, and sexual and reproductive health issues from 2018 to 2022. Funding to US government agencies reflects self-funding and/or transfers from other agencies. Some industry data is anonymized and aggregated. See methodology for additional details.
*Organization appears to be closed/out of business.
Jobs created: Based on author’s analysis described above and previous analysis assessing jobs created per state from US National Institutes of Health funding. See methodology for additional details.
Neglected and emerging diseases: Reflects US Centers for Disease Control and Prevention data for: Chikungunya virus cases 2014–2022, Dengue virus infection cases 2010-2021, HIV diagnoses 2008–2022, Malaria cases 2007–2022, Mpox cases 2022–March 29, 2023, Tuberculosis cases 2007–2021, Viral hemorrhagic fever cases 2007-2022, and Zika virus disease cases 2015–2021.
Case study photo: PATH/Patrick McKern